<DOC>
	<DOCNO>NCT00061516</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy BETAXON AZOPT pediatric patient . Patients dose study drug 8 8 pm daily twelve week . Patients vision test , slit lamp exam , blood pressure pulse check visit . Patients dilate fundus exam corneal measurement take first last visit .</brief_summary>
	<brief_title>Safety Efficacy Study BETAXON 0.5 % AZOPT 1.0 % Pediatric Patients With Glaucoma Ocular Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Brinzolamide</mesh_term>
	<criteria>INCLUSION : Children 5 year old young require treatment glaucoma ocular hypertension vision 20/80 good cuptodisc ratio 0.8 less EXCLUSION : abnormal fixation IOP great 36 mm Hg significant retinal disease penetrate keratoplasty severe ocular pathology optic atrophy eye surgery past 30 day cardiovascular abnormality hypersensitivity beta blocker , carbonic anhydrase inhibitor sulfa drug</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>5 Years</maximum_age>
	<verification_date>August 2008</verification_date>
	<keyword>Glaucoma</keyword>
	<keyword>Ocular Hypertension</keyword>
</DOC>